ResMed Inc. (RMD)
ResMed is a medical technology company that designs and manufactures devices to help people with sleep-related breathing disorders, like sleep apnoea.
Is ResMed Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Strong profit margins showing a healthy core business. Worth weighing: Recent negative share price performance. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has ResMed Inc. actually fallen?
Over the last 2 years of daily prices, ResMed Inc. fell as much as −38% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Dominance in the digital health and remote monitoring space.
Technological disruption making current devices obsolete.
What does ResMed Inc. do?
ResMed makes the machines, masks, and software that help people breathe properly while they sleep. Income flows from selling these devices to patients and healthcare providers, along with digital services that help doctors track how well a patient's treatment is working. How they handle competition will be telling, especially as new weight-loss drugs grow more popular and some worry this might reduce the long-term need for their breathing devices.
On our factor screen it looks strongest on quality and income, and weakest on momentum.
- ✓Pays a dividend - about 1.1% a year
- ✓Growing - revenue up about 11% over the year
- ✓Very profitable - turns about 27% of sales into profit
- ✓Low debt - a sturdier balance sheet
- ✓Strong return on shareholder money (ROE 25%)
- Quality screens high (80/100)
- Strong profit margins showing a healthy core business
- High return on equity suggests efficient management
- Essential nature of products provides a steady customer base
- Momentum screens low (31/100)
- Competition from new weight-loss medications
- Potential for government healthcare budget cuts
- Dependence on global supply chains for manufacturing
What do ResMed Inc.'s numbers mean?
How much money does ResMed Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does ResMed Inc. pay a dividend?
Yes - ResMed Inc. currently pays a dividend of about 1.1% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
What do the numbers say about ResMed Inc.'s dividend?
There's no rating here, and we don't judge whether the dividend will continue - that would be advice. Here are the figures income investors usually look at, and what each one means, so you can weigh it up yourself.
Figures are from the latest available data and can be distorted by one-off results. Past payments don't predict future ones, and a dividend can be cut at any time. This lays out the numbers to help you understand them - it is not a view on what will happen.
When does ResMed Inc. report earnings, and how did recent quarters go?
ResMed Inc. is next scheduled to report on about 2026-08-06 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-04-30 | $2.80 | $2.86 | Beat +2% |
| 2026-01-29 | $2.72 | $2.81 | Beat +3% |
| 2025-10-30 | $2.50 | $2.55 | Beat +2% |
| 2025-07-31 | $2.48 | $2.55 | Beat +3% |
| 2025-04-23 | $2.36 | $2.37 | In line |
| 2025-01-30 | $2.31 | $2.43 | Beat +5% |
Across the last 6 quarters here, ResMed Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for ResMed Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of ResMed Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Strong profit margins showing a healthy core business
- High return on equity: How much profit the company makes for each £1 shareholders have put in. Higher usually means a more efficient business. suggests efficient management
- Essential nature of products provides a steady customer base
- Recent negative share price performance
- Relatively low dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone. compared to other sectors
- High reliance on a specific niche of medical devices
- Competition from new weight-loss medications
- Potential for government healthcare budget cuts
- Dependence on global supply chains for manufacturing
The write-up's own warning lights — if these start happening, the case above changes.
- A significant drop in the number of patients diagnosed with sleep disorders
- A major breakthrough in non-device treatments for sleep apnoea
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.